Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for moyamoya disease 3 has been reported in the published literature.
No clinical trials have been registered for moyamoya disease 3.
6 publications have been identified in PubMed for moyamoya disease 3. Research spans Diagnostic / Biomarker (17%), Review / Meta-Analysis (17%), and Case Report / Case Series (17%).
Zhu Y (2025). [PMID: 38845225](https://pubmed.ncbi.nlm.nih.gov/38845225/). *Neural regeneration research*. [Review / Meta-Analysis]
Imai R (2025). [PMID: 39944439](https://pubmed.ncbi.nlm.nih.gov/39944439/). *Cureus*. [Diagnostic / Biomarker]
Uchino H (2025). [PMID: 40301050](https://pubmed.ncbi.nlm.nih.gov/40301050/). *Neurologia medico-chirurgica*. [Gene Therapy / Novel Therapeutics]
Manara R (2025). [PMID: 41291755](https://pubmed.ncbi.nlm.nih.gov/41291755/). *Orphanet journal of rare diseases*. [Epidemiology / Natural History]
Shivashankar T (2025). [PMID: 41180760](https://pubmed.ncbi.nlm.nih.gov/41180760/). *Annals of medicine and surgery (2012)*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 10:29 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
AI-curated news mentioning moyamoya disease 3
Updated Sep 18, 2026
A recent meta-regression study explores the prediction of cerebral hyperperfusion syndrome following STA-MCA bypass in patients with moyamoya disease using CT perfusion techniques. This research could enhance surgical outcomes and patient management strategies.
A systematic review highlights cognitive deficits in patients with non-revascularized moyamoya disease, emphasizing the need for neuropsychological assessments. This research provides insights into the cognitive challenges faced by this patient population.
A case report details an unusual presentation of moyamoya disease managed conservatively in a resource-limited region. This study contributes to the understanding of the disease's variability and management options.